163 related articles for article (PubMed ID: 11242797)
1. Cyclin D3 expression in non-Hodgkin lymphoma. Correlation with other cell cycle regulators and clinical features.
Møller MB; Nielsen O; Pedersen NT
Am J Clin Pathol; 2001 Mar; 115(3):404-12. PubMed ID: 11242797
[TBL] [Abstract][Full Text] [Related]
2. Molecular control of the cell cycle in cancer: biological and clinical aspects.
Møller MB
Dan Med Bull; 2003 May; 50(2):118-38. PubMed ID: 12812137
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters.
Lopez-Beltran A; Luque RJ; Alvarez-Kindelan J; Quintero A; Merlo F; Requena MJ; Montironi R
Am J Clin Pathol; 2004 Sep; 122(3):444-52. PubMed ID: 15362377
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1).
Lopez-Beltran A; Luque RJ; Alvarez-Kindelan J; Quintero A; Merlo F; Carrasco JC; Requena MJ; Montironi R
Eur Urol; 2004 May; 45(5):606-12. PubMed ID: 15082203
[TBL] [Abstract][Full Text] [Related]
5. Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1.
Korkolopoulou P; Christodoulou P; Konstantinidou AE; Thomas-Tsagli E; Kapralos P; Davaris P
Hum Pathol; 2000 Jun; 31(6):751-60. PubMed ID: 10872671
[TBL] [Abstract][Full Text] [Related]
6. p27KIP1 is abnormally expressed in Diffuse Large B-cell Lymphomas and is associated with an adverse clinical outcome.
Sáez A; Sánchez E; Sánchez-Beato M; Cruz MA; Chacón I; Muñoz E; Camacho FI; Martínez-Montero JC; Mollejo M; García JF; Piris MA
Br J Cancer; 1999 Jul; 80(9):1427-34. PubMed ID: 10424746
[TBL] [Abstract][Full Text] [Related]
7. Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma.
Filipits M; Jaeger U; Pohl G; Stranzl T; Simonitsch I; Kaider A; Skrabs C; Pirker R
Clin Cancer Res; 2002 Mar; 8(3):729-33. PubMed ID: 11895902
[TBL] [Abstract][Full Text] [Related]
8. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
Ioachim E
Int J Clin Pract; 2008 Nov; 62(11):1736-43. PubMed ID: 19143860
[TBL] [Abstract][Full Text] [Related]
9. Disrupted p53 function as predictor of treatment failure and poor prognosis in B- and T-cell non-Hodgkin's lymphoma.
Møller MB; Gerdes AM; Skjødt K; Mortensen LS; Pedersen NT
Clin Cancer Res; 1999 May; 5(5):1085-91. PubMed ID: 10353742
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent kinase inhibitor p27KIP1 in lymphoid tissue: p27KIP1 expression is inversely proportional to the proliferative index.
Sánchez-Beato M; Sáez AI; Martínez-Montero JC; Sol Mateo M; Sánchez-Verde L; Villuendas R; Troncone G; Piris MA
Am J Pathol; 1997 Jul; 151(1):151-60. PubMed ID: 9212741
[TBL] [Abstract][Full Text] [Related]
11. Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers.
Migaldi M; Sgambato A; Garagnani L; Ardito R; Ferrari P; De Gaetani C; Cittadini A; Trentini GP
Clin Cancer Res; 2000 Aug; 6(8):3131-8. PubMed ID: 10955794
[TBL] [Abstract][Full Text] [Related]
12. Expression and prognostic implications of cell cycle regulatory molecules, p16, p21, p27, p14 and p53 in germinal centre and non-germinal centre B-like diffuse large B-cell lymphomas.
Paik JH; Jeon YK; Park SS; Kim YA; Kim JE; Huh J; Lee SS; Kim WH; Kim CW
Histopathology; 2005 Sep; 47(3):281-91. PubMed ID: 16115229
[TBL] [Abstract][Full Text] [Related]
13. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer.
Bali A; O'Brien PM; Edwards LS; Sutherland RL; Hacker NF; Henshall SM
Clin Cancer Res; 2004 Aug; 10(15):5168-77. PubMed ID: 15297421
[TBL] [Abstract][Full Text] [Related]
14. Low expression of p27 protein combined with altered p53 and Rb/p16 expression status is associated with increased expression of cyclin A and cyclin B1 in diffuse large B-cell lymphomas.
Bai M; Vlachonikolis J; Agnantis NJ; Tsanou E; Dimou S; Nicolaides C; Stefanaki S; Pavlidis N; Kanavaros P
Mod Pathol; 2001 Nov; 14(11):1105-13. PubMed ID: 11706071
[TBL] [Abstract][Full Text] [Related]
15. Cyclin D3 expression in primary Ta/T1 bladder cancer.
Lopez-Beltran A; Requena MJ; Luque RJ; Alvarez-Kindelan J; Quintero A; Blanca AM; Rodriguez ME; Siendones E; Montironi R
J Pathol; 2006 May; 209(1):106-13. PubMed ID: 16482499
[TBL] [Abstract][Full Text] [Related]
16. Cell cycle dysregulation influences survival in high risk breast cancer patients.
Königsberg R; Rögelsperger O; Jäger W; Thalhammer T; Klimpfinger M; De Santis M; Hudec M; Dittrich C
Cancer Invest; 2008 Aug; 26(7):734-40. PubMed ID: 18665474
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical study of cell cycle-associated proteins in adenocarcinoma of the uterine cervix treated with radiotherapy alone: P53 status has a strong impact on prognosis.
Suzuki Y; Nakano T; Kato S; Ohno T; Tsujii H; Oka K
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):231-6. PubMed ID: 15337561
[TBL] [Abstract][Full Text] [Related]
18. Expression of the cyclin-dependent kinase inhibitor p27 and its deregulation in mouse B cell lymphomas.
Qi CF; Xiang S; Shin MS; Hao X; Lee CH; Zhou JX; Torrey TA; Hartley JW; Fredrickson TN; Morse HC
Leuk Res; 2006 Feb; 30(2):153-63. PubMed ID: 16122798
[TBL] [Abstract][Full Text] [Related]
19. Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators.
Korkolopoulou P; Givalos N; Saetta A; Goudopoulou A; Gakiopoulou H; Thymara I; Thomas-Tsagli E; Patsouris E
Hum Pathol; 2005 Aug; 36(8):899-907. PubMed ID: 16112007
[TBL] [Abstract][Full Text] [Related]
20. Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin's lymphoma.
Møller MB; Nielsen O; Pedersen NT
Histopathology; 2002 Oct; 41(4):322-30. PubMed ID: 12383214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]